Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission

References

• Siegel R, Ma J, Zou Z, et al. Cancer statistics. CA Cancer J Clin. 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Lazarevic V, Hörstedt AS, et al. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119:3890–3899.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179–4187.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235–1248.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011;152:524–542.
   PubMed Web of Science ®Google Scholar
• Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125:767–774.
   PubMed Web of Science ®Google Scholar
• Mohty M, de Lavallade H, Ladaique P, et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia. 2005;19:916–920.
   PubMed Web of Science ®Google Scholar
• Farag SS, Maharry K, Zhang MJ, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60–70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011;17:1796–1803.
   PubMed Web of Science ®Google Scholar
• Tokita K, Terasaki P, Maruya E, et al. Tumour regression following stem cell infusion from daughter to microchimeric mother. Lancet. 2001;358:2047–2048.
   PubMed Web of Science ®Google Scholar
• Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood. 2006;107:3430–3435.
   PubMed Web of Science ®Google Scholar
• Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood. 2011;117:936–941.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670–2677.
   PubMed Web of Science ®Google Scholar
• Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54:2003–2007.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97:393–401.
   PubMed Web of Science ®Google Scholar
• Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res. 2007;13:4225–4232.
   PubMed Web of Science ®Google Scholar
• Li J, Chen Y, Zhu Y, et al. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget. 2015;6:6448–6458.
   PubMed Web of Science ®Google Scholar
• Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119:3361–3369.
   PubMed Web of Science ®Google Scholar
• Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116:129–139.
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Tallman MS, Abboud CN, et al. NCCN clinical practice guidelines in acute myeloid leukemia (Version 1.2017). [Internet]; 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
   Google Scholar
• Guo M, Hu KX, Liu GX, et al. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up. J Clin Oncol. 2012;30:4084–4090.
   PubMed Web of Science ®Google Scholar
• Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia. 1995;9:10–14.
   PubMed Web of Science ®Google Scholar
• Qian SX, Li JY, Tian T, et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res. 2007;31:1383–1388.
   PubMed Web of Science ®Google Scholar
• Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol. 2000;71:238–244.
   PubMed Web of Science ®Google Scholar
• Marshall NA, Howe JG, Formica R, et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood. 2000;96:2814–2821.
   PubMed Web of Science ®Google Scholar
• Porter DL, Connors JM, Van Deerlin VM, et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol. 1999;17:1234–1243.
   PubMed Web of Science ®Google Scholar
• Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia. 2006;20:1690–1700.
   PubMed Web of Science ®Google Scholar
• Kwon YR, Son MJ, Kim HJ, et al. Reactivation of silenced WT1 transgene by hypomethylating agents - implications for in vitro modeling of chemoimmunotherapy. Immune Netw. 2012;12:58–65.
   PubMedGoogle Scholar
• Kim YJ, Cho SG, Lee S, et al. Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML. Bone Marrow Transplant. 2010;45:597–599.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong AS, Savani BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood. 2007;110:1924–1932.
   PubMed Web of Science ®Google Scholar
• Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007;445:771–775.
   PubMed Web of Science ®Google Scholar
• Janson PC, Winerdal ME, Martis P, et al. FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS One. 2008;3:e1612.
   PubMed Web of Science ®Google Scholar
• Fondi C, Nozzoli C, Benemei S, et al. Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response. Biol Blood Marrow Transplant. 2009;15:938–947.
   PubMed Web of Science ®Google Scholar